BioSpace News Archive

New campaign promotes the importance of an individual rescue plan for those…just in case moments!

Alkermes plc and Biogen Inc. announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis, compared to TECFIDERA®.

Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6, 2019.

MedTest Dx’s Extensive Line of Pointe Scientific Branded Reagents Manufactured in the U.S. Now Comes with a Worry-Free Certified Performance Guarantee

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019.

Waters Corporation announced second quarter 2019 sales of $599 million, which were flat as reported, compared to sales of $596 million for the second quarter of 2018.

Webcast scheduled for Wednesday, August 7th at 11:30 a.m. Eastern Time

Cantel Medical Corp., a global leader in instrument reprocessing and innovative infection prevention products and services, announced that it has entered into a definitive agreement to acquire privately-held Hu-Friedy Mfg.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that the first patient has been enrolled in the RELIEF Phase 2 study of BLU-5937 in chronic cough.

Infinity Pharmaceuticals, Inc. announced its second quarter 2019 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma inhibition.